Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00510445 · ClinicalTrials.gov registry record · Phase 1
Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
A Phase 1 study, sponsored by Geron Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00510445 is a Phase 1 study that has completed, run by Geron Corporation. The registered enrollment target is 27 participants.
The verdict
NCT00510445, a Phase 1 study, has completed, sponsored by Geron Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and the maximum tolerated dose (MTD) of GRN163L when administered in combination with a standard paclitaxel/carboplatin regimen to patients with advanced or metastatic non-small cell lung cancer.
Interventions
- DRUG Imetelstat Sodium (GRN163L)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00510445
The ClinicalTrials.gov registry entry for NCT00510445 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geron Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imetelstat Sodium (GRN163L) is the first listed.
NCT00510445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00510445 about?
NCT00510445 is a clinical study titled "Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer". The purpose of this study is to determine the safety and the maximum tolerated dose (MTD) of GRN163L when administered in combination with a standard paclitaxel/carboplatin regimen to patients with advanced or metastatic non-small cell lung cancer.
What is the current status of trial NCT00510445?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2007-07. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00510445?
The interventions under investigation include: Imetelstat Sodium (GRN163L) (DRUG).
Who is sponsoring clinical trial NCT00510445?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.